| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
227.84(M) |
| Last
Volume: |
2,211,986 |
Avg
Vol: |
2,301,679 |
| 52
Week Range: |
$0.449 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
86,265 |
122,918 |
235,260 |
541,068 |
| Total Sell Value |
$152,594 |
$177,518 |
$247,417 |
$1,284,611 |
| Total People Sold |
4 |
4 |
7 |
10 |
| Total Sell Transactions |
4 |
7 |
16 |
37 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Thomsen Jillian B. |
Chief Financial Officer |
• – – |
2022-11-16 |
4 |
S |
$3.57 |
$39,609 |
D/D |
(11,095) |
323,764 |
|
82% |
|
| Robin Howard W |
President & CEO |
• • – |
2022-11-16 |
4 |
S |
$3.57 |
$135,710 |
D/D |
(38,014) |
979,793 |
|
82% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2022-11-16 |
4 |
S |
$3.57 |
$48,052 |
D/D |
(13,460) |
313,663 |
|
82% |
|
| Myriam Curet |
Director |
– • – |
2022-09-23 |
4 |
S |
$3.16 |
$13,266 |
D/D |
(4,198) |
31,777 |
|
2% |
|
| Ajer Jeffrey Robert |
Director |
– • – |
2022-09-23 |
4 |
S |
$3.16 |
$13,266 |
D/D |
(4,198) |
38,512 |
|
2% |
|
| Chess Robert |
Director |
– • – |
2022-09-22 |
4 |
AS |
$0.67 |
$6,834 |
D/D |
(10,200) |
274,773 |
|
-4% |
|
| Chess Robert |
Director |
– • – |
2022-09-22 |
4 |
AS |
$3.19 |
$16,269 |
D/D |
(5,100) |
228,179 |
|
-4% |
|
| Chess Robert |
Director |
– • – |
2022-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,200 |
233,279 |
|
- |
|
| Ajer Jeffrey Robert |
Director |
– • – |
2022-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,200 |
42,710 |
|
- |
|
| Eastham Karin |
Director |
– • – |
2022-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,200 |
23,233 |
|
- |
|
| Whitfield Roy A |
Director |
– • – |
2022-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,200 |
246,250 |
|
- |
|
| Brainard Diana |
Director |
– • – |
2022-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,200 |
28,560 |
|
- |
|
| Myriam Curet |
Director |
– • – |
2022-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,200 |
35,975 |
|
- |
|
| Greer R Scott |
Director |
– • – |
2022-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,200 |
303,574 |
|
- |
|
| Eastham Karin |
Director |
– • – |
2022-09-13 |
4 |
AS |
$3.61 |
$76,774 |
D/D |
(21,267) |
13,033 |
|
-34% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2022-08-18 |
4 |
AS |
$4.65 |
$342,779 |
D/D |
(73,716) |
327,123 |
|
-53% |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2022-08-16 |
4 |
S |
$4.76 |
$9,549 |
D/D |
(2,006) |
334,859 |
|
56% |
|
| Robin Howard W |
President & CEO |
• • – |
2022-08-16 |
4 |
S |
$4.76 |
$65,493 |
D/D |
(13,759) |
1,017,807 |
|
56% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2022-08-16 |
4 |
S |
$4.76 |
$50,266 |
D/D |
(10,560) |
400,839 |
|
56% |
|
| Wilson Mark Andrew |
SVP & General Counsel |
• – – |
2022-08-16 |
4 |
S |
$4.76 |
$15,180 |
D/D |
(3,189) |
281,188 |
|
56% |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
165,938 |
336,865 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
410,625 |
1,031,566 |
|
- |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
135,000 |
411,399 |
|
- |
|
| Wilson Mark Andrew |
SVP & General Counsel |
• – – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
165,938 |
284,377 |
|
- |
|
| Wilson Mark Andrew |
SVP & General Counsel |
• – – |
2022-05-16 |
4 |
S |
$3.95 |
$12,387 |
D/D |
(3,136) |
117,939 |
|
21% |
|
913 Records found
|
|
Page 2 of 37 |
|
|
0.01 (0.79%) 
